Top 2 Cannabis Stocks to Buy for the Next Decade

While the cannabis stocks have burnt massive investor wealth, two companies may offer significant upside potential for long-term investors.

| More on:

While the equity markets have recently entered bear markets, cannabis investors have seen a steady decline in their portfolio value for the last 12 months. Several pot stocks are down close to 80% from record highs, wiping out millions in market value.

We know that cannabis companies are grappling with lower-than-expected demand due to the slow rollout of retail stores in major Canadian provinces. As these provinces start increasing the number of licenses, inventory levels of several marijuana companies will move lower, thereby reducing the number of write-offs.

The cannabis industry is still at a nascent stage and is expected to grow at an exponential rate in the coming years. So while most pot stocks are at 52-week lows, the upside potential is massive.

Here we look at two such cannabis stocks that are solid bets for the coming decade.

MediPharm Labs is trading 79% below record highs

Shares of MediPharm Labs (TSX:LABS) are trading at $1.59, which is 79% below record highs. This Canada-based company specializes in pharmaceutical-grade production of cannabis. It focuses on distillation and cannabinoid isolation and purification.

It has a 70,000 square foot facility with a production capacity of 30,000 kilograms. The company has spent significant resources to develop advanced extraction technology and provide safe and accurately measured cannabis products to customers.

Last May, MediPharm announced a supply agreement with Cronos Group. According to this contract, MediPharm will supply Cronos with $30 million of cannabis concentrate over the next 18 months — a figure that’s expected to rise to $60 million in two years.

In September 2019, MediPharm entered into a two-year manufacturing agreement with Cronos for filling and packaging of vaping devices.

These agreements will result in a steady stream of income for MediPharm. Unlike most cannabis stocks, however, MediPharm is posting an adjusted net profit. According to consensus estimates, the company’s revenue is expected to touch $133.7 million in 2019 and $187 million in 2020, up from $7.67 million in 2018.

A price-to-earnings multiple of 11.4 and a price to 2020 sales ratio of 1.11 makes MediPharm one of the cheapest marijuana companies in Canada.

A cannabis landlord

What’s better than a profitable pot stock? One that pays a dividend. Innovative Industrial Properties (NYSE:IIPR) is a cannabis-focused real estate investment trust. The company acquires, owns and manages properties leased to licensed operators. IIPR acquires properties through sale-leaseback transactions and third-party purchases.

Cannabis is still illegal at the federal level in the United States, which makes it difficult for companies to raise debt capital. That’s where IIPR comes in, making it easier for licensed producers to focus on manufacturing on top-quality products and cut capital spending on property acquisition.

IIPR continues to grow top-line by property acquisition. It now owns 51 properties totaling 3.2 million square feet with an average lease term of 15.6 years.

IIPR stock is currently trading 63% below record highs, which has increased its dividend yield to a tasty 8.6%. This cannabis REIT is trading at an attractive forward price to earnings multiple of 14, while analysts expect earnings to grow by 81.3% in 2020 and 55.4% in 2021.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool owns shares of and recommends Innovative Industrial Properties. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »